[go: up one dir, main page]

WO2011063776A3 - Soluble beta-glucan-api complexes for pharmaceutical use - Google Patents

Soluble beta-glucan-api complexes for pharmaceutical use Download PDF

Info

Publication number
WO2011063776A3
WO2011063776A3 PCT/CZ2010/000122 CZ2010000122W WO2011063776A3 WO 2011063776 A3 WO2011063776 A3 WO 2011063776A3 CZ 2010000122 W CZ2010000122 W CZ 2010000122W WO 2011063776 A3 WO2011063776 A3 WO 2011063776A3
Authority
WO
WIPO (PCT)
Prior art keywords
water
soluble
glucan
complexes
apis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CZ2010/000122
Other languages
French (fr)
Other versions
WO2011063776A2 (en
Inventor
Vladimir Kral
Jarmila Kralova
Kamil Zaruba
Miroslav Flieger
Zdenek Kejik
Pavel Martasek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of WO2011063776A2 publication Critical patent/WO2011063776A2/en
Anticipated expiration legal-status Critical
Publication of WO2011063776A3 publication Critical patent/WO2011063776A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention relates to new water-soluble beta-glucan complexes with active pharmaceutical ingredients (APIs) and their pharmaceutical compositions. The formation of water soluble complexes according to the invention is achieved by addition of an API solution in an organic solvent (preferentially, 2-propanol, tetrahydrofuran, dioxane) to the solution of water-soluble glucan with control of the water/organic solvent ratio. For water-soluble APIs, such as doxorubicin, the complex is formed by addition of the solution of API to an aqueous glucan solution, followed by addition of a water-miscible organic solvent leading to conformation change of glucan and consequently to complex formation. The invention provides new water-soluble complexes of water-insoluble APIs and new slow release forms of water-soluble APIs. The preparation according to the invention could be applied for variety of formulation strategies, including oral drug products.
PCT/CZ2010/000122 2009-11-25 2010-11-25 Soluble beta-glucan-api complexes for pharmaceutical use Ceased WO2011063776A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20090790A CZ302789B6 (en) 2009-11-25 2009-11-25 Method of increasing solubility of pharmaceutically active compounds and targeted (controlled) transport thereof into intestine
CZPV2009-790 2009-11-25

Publications (2)

Publication Number Publication Date
WO2011063776A2 WO2011063776A2 (en) 2011-06-03
WO2011063776A3 true WO2011063776A3 (en) 2012-05-31

Family

ID=43743524

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/CZ2010/000120 Ceased WO2011063774A2 (en) 2009-11-25 2010-11-25 Pectin complexes of steroids and pharmaceutical compositions based thereon
PCT/CZ2010/000121 Ceased WO2011063775A2 (en) 2009-11-25 2010-11-25 Pectin complexes of sartans and pharmaceutical compositions based thereon
PCT/CZ2010/000122 Ceased WO2011063776A2 (en) 2009-11-25 2010-11-25 Soluble beta-glucan-api complexes for pharmaceutical use

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/CZ2010/000120 Ceased WO2011063774A2 (en) 2009-11-25 2010-11-25 Pectin complexes of steroids and pharmaceutical compositions based thereon
PCT/CZ2010/000121 Ceased WO2011063775A2 (en) 2009-11-25 2010-11-25 Pectin complexes of sartans and pharmaceutical compositions based thereon

Country Status (2)

Country Link
CZ (1) CZ302789B6 (en)
WO (3) WO2011063774A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014176531A2 (en) * 2013-04-27 2014-10-30 The Regents Of The University Of California Co-solvent to produce reactive intermediates from biomass
CN103622928A (en) * 2013-11-27 2014-03-12 广西大学 Preparation method and application of pectin-base carrier material
WO2019046582A1 (en) 2017-08-30 2019-03-07 Antares Pharma, Inc. Testosterone ester triglyceride formulations
CN115252587A (en) * 2022-08-19 2022-11-01 南京泛太化工医药研究所 Oral instant film and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392487A2 (en) * 1989-04-13 1990-10-17 Takeda Chemical Industries, Ltd. Stabilized composition of anthracyclines
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
WO2006015627A1 (en) * 2004-08-13 2006-02-16 Symrise Gmbh & Co. Kg β-(1,3)-β-(1,4)-GLUCAN AS CARRIER FOR CHEMICAL SUBSTANCES
US20070213393A1 (en) * 2001-05-01 2007-09-13 Angiotech International Ag Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950689A (en) 1987-03-31 1990-08-21 Yang Robert K Pectin delivery system
GB9004950D0 (en) * 1990-03-06 1990-05-02 Kelco Int Ltd Controlled release formulation
SE9002339L (en) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab THERAPEUTIC COMPOSITION AND PROCEDURE FOR ITS PREPARATION
RO107187B1 (en) 1992-02-11 1993-10-29 Icn Galenika Sa Antiacid stabilized pharmaceutical composition and preparation process therefor
HU213872B (en) * 1993-09-08 1997-11-28 Mta Koezponti Kemiai Kutato In Oligo- and polygalacturonate mixed complex, pharmaceutical and food compositions containing them, further process for preparing these compounds
KR0121127B1 (en) 1994-05-09 1997-11-13 강박광 Transdermal drug delivery system having ionic polymer network
US5849327A (en) 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
DK0876142T3 (en) * 1996-01-16 2001-11-19 Advanced Polymer Systems Inc Topical administration of drugs to the lower gastrointestinal tract
IT1282381B1 (en) 1996-04-29 1998-03-20 Trans Bussan S A NEW FORMULATIONS OF DIACEREIN, OBTAINED BY INCLUSION OF THE ACTIVE INGREDIENT IN HYDROGEL POLYSACCHARIDES
IL127189A0 (en) 1996-05-22 1999-09-22 Diversified Pharmaceuticals In Compositions methods and devices for the transdermal delivery of drugs
US5891441A (en) 1996-07-08 1999-04-06 Diaz; Jose A. Chemical composition and method for more rapidly aiding the absorption, binding an elimination of undigested fat in the human body
US6200574B1 (en) 1996-07-08 2001-03-13 Jose A. Diaz Chemical composition for aiding the absorption, binding and elimination of undigested fat
FR2752843B1 (en) * 1996-08-30 1998-10-16 Sod Conseils Rech Applic CROSSLINKED COPOLYMERS BASED ON POLYCARBOXYLIC POLYMERS AND THEIR USE AS SUPPORTS OF PHARMACEUTICAL COMPOSITIONS
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US20040136961A1 (en) 1997-10-09 2004-07-15 Ales Prokop Nanoparticulate composition for efficient gene transfer
US6337091B1 (en) * 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
AU751182B2 (en) 1997-12-02 2002-08-08 Archimedes Development Limited Compositions for nasal administration
US6313103B1 (en) 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
KR20000011247A (en) 1998-07-23 2000-02-25 김윤 Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
RU2169002C2 (en) 1999-04-19 2001-06-20 Пятигорская государственная фармацевтическая академия Method of preparing inulin-pectin concentrate powder for medicinal and food aims from dried raw
AU2002243267A1 (en) 2000-10-27 2002-06-24 Mannatech, Inc. Dietary supplement compositions
WO2003004033A1 (en) 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
JP4339685B2 (en) 2001-09-03 2009-10-07 ディーエスエム アイピー アセッツ ビー．ブイ． Composition comprising pectin and ascorbic acid
JP2003127783A (en) 2001-10-25 2003-05-08 Mitsuboshi Belting Ltd Floor console
DE10212553A1 (en) 2002-03-16 2003-09-25 Knoell Hans Forschung Ev Acceleration of the biodegradation of porous wound coverings based on polyhydroxyalkanoate and polyanionic hydrocolloids is effected using a buffered formulation containing a poly-(hydroxybutyrate)-depolymerase
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US20050089572A1 (en) 2002-03-22 2005-04-28 Manoj Kumar Controlled release drug delivery system of pravastatin
DE10214005A1 (en) 2002-03-27 2003-10-09 Volker Bartz Orally administered dietetic, nutritional supplement or medicament composition, useful as hypolipemic agent, comprising mixture of pectin and/or guar powder with eicosapentaenoic and docosahexaenoic acids
DE20205184U1 (en) 2002-03-27 2002-12-19 Bartz, Volker, 35440 Linden Blood lipid lowerers for oral use
DE10250083A1 (en) 2002-06-17 2003-12-24 Gruenenthal Gmbh Dosage form protected against abuse
KR100522239B1 (en) * 2002-07-16 2005-10-18 주식회사 서울제약 Compositions for controlled release acetaminophen dosage forms
JP2004059440A (en) 2002-07-25 2004-02-26 Mikasa Seiyaku Co Ltd Skin roughening preventing and mucosal repair agent
US20040087514A1 (en) 2002-09-06 2004-05-06 Hughes Thomas E Nutritional compositions
JP2004107295A (en) 2002-09-20 2004-04-08 National Agriculture & Bio-Oriented Research Organization Histamine release inhibitor
US6703044B1 (en) 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
CZ296475B6 (en) 2002-12-09 2006-03-15 Mikrobiologický Ústav Av Cr Fermentation process and isolation of extracellular glucan using Claviceps species fungi
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040241223A1 (en) 2003-05-27 2004-12-02 David Wong Oral dosage forms for macromolecular drugs
CN100477999C (en) 2003-12-29 2009-04-15 湖南华纳大药厂有限公司 Dispersible tablet of colloid petcin
IL160095A0 (en) 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
WO2005084648A1 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
JPWO2005084703A1 (en) 2004-03-09 2007-11-29 株式会社Ｎｒｌファーマ Sustained release oral composition
DE102004019916A1 (en) 2004-04-21 2005-11-17 Grünenthal GmbH Anti-abuse drug-containing patch
WO2005105040A2 (en) 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
JP2008503583A (en) 2004-06-22 2008-02-07 プロ−ファーマシューティカルズ，インコーポレイティド Compositions and methods for co-delivery of anti-cancer agents, anti-angiogenic agents, and polysaccharides
CN101039699B (en) * 2004-10-15 2011-07-27 柳署弘 Methods and compositions for reducing toxicity of a pharmaceutical compound
CA2595526A1 (en) * 2005-02-09 2006-08-17 Da Volterra Colonic delivery of active agents
ITBO20050123A1 (en) 2005-03-07 2005-06-06 Alfa Wassermann Spa GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA
WO2006122835A1 (en) 2005-05-18 2006-11-23 Da Volterra Colonic delivery of adsorbents
CN100340295C (en) 2005-06-29 2007-10-03 山西安特生物制药股份有限公司 Oral administered compound colloid pectin bismuth preparation and its preparing process
ES2279695B1 (en) 2005-08-01 2008-08-01 Jesus Antas Pharma, S.A. NEW SOLID FORMULATIONS OF CAROTENOIDS AND PROCEDURE FOR OBTAINING.
JP4817042B2 (en) 2005-08-26 2011-11-16 国立大学法人三重大学 Method for producing group III nitride crystal containing Al, and group III nitride crystal containing Al
US20070167395A1 (en) 2006-01-17 2007-07-19 Isaac Eliaz Compositions and methods for treating diabetes
KR101234799B1 (en) * 2006-02-07 2013-02-20 삼성전자주식회사 Method and apparatus for controlling movement of robot
KR100912680B1 (en) * 2006-03-16 2009-08-19 (주) 벡스코아 Controlled release formulation
CN101045163B (en) 2006-03-29 2011-03-30 重庆莱美药业股份有限公司 High molecular anticarcinogenic prodrug, its preparing method and use
PT103476B (en) 2006-05-10 2008-09-19 Univ De Coimbra PRODUCTION AND INSULATION PROCESS OF POLYMERIC MICRO- AND NANOPARTICLES CONTAINING MACROMOLECULES OF HYDROFYLIC AND THERMOLIBLE NATURE
CN100394923C (en) 2006-05-26 2008-06-18 范晓青 Application of low molecular citrus pectin in regulation of blood sugar, blood fat and improvement of fatty liver
US20070292480A1 (en) 2006-06-14 2007-12-20 Conopco, Inc., D/B/A Unilever Delivery System for Ingestible Components
CN101528224A (en) * 2006-09-05 2009-09-09 阿斯利康(瑞典)有限公司 Pharmaceutical composition comprising candesartan cilexetil
EP2081557A1 (en) 2006-11-17 2009-07-29 DA Volterra Colonic delivery using zn/pectin beads with a eudragit coating.
US20090018175A1 (en) * 2007-04-25 2009-01-15 Itamar Kanari Pharmaceutical excipient complex
EP2172193A1 (en) * 2008-10-02 2010-04-07 Capsulution Nanoscience AG Improved nanoparticulate compositions of poorly soluble compounds
CZ20098A3 (en) * 2009-01-13 2010-07-21 Zentiva, K.S. Medicinal forms of tyrosine kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392487A2 (en) * 1989-04-13 1990-10-17 Takeda Chemical Industries, Ltd. Stabilized composition of anthracyclines
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US20070213393A1 (en) * 2001-05-01 2007-09-13 Angiotech International Ag Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
WO2006015627A1 (en) * 2004-08-13 2006-02-16 Symrise Gmbh & Co. Kg β-(1,3)-β-(1,4)-GLUCAN AS CARRIER FOR CHEMICAL SUBSTANCES

Also Published As

Publication number Publication date
WO2011063776A2 (en) 2011-06-03
WO2011063774A3 (en) 2012-01-19
CZ302789B6 (en) 2011-11-09
WO2011063775A3 (en) 2012-01-26
CZ2009790A3 (en) 2011-06-01
WO2011063774A2 (en) 2011-06-03
WO2011063775A2 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
WO2008005819A3 (en) Ophthalmic formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
WO2009019571A3 (en) Method of dissolving essential oils in water
WO2009066457A1 (en) External preparation composition comprising fatty acid-based ionic liquid as active ingredient
IN2011KN04251A (en)
MX2011007817A (en) Controlled release pharmaceutical or food formulation and process for its preparation.
WO2011113855A3 (en) Pharmaceutical composition for treatment of increased intraocular pressure
WO2012064126A3 (en) Medical adhesive composition
WO2010119369A3 (en) A medicinal cream made using silver sulphadiazine and chitosan and a process to make it
WO2007121352A3 (en) Therapeutic triterpenoids
WO2011063776A3 (en) Soluble beta-glucan-api complexes for pharmaceutical use
WO2010045281A3 (en) Stable aqueous formulations of water insoluble or poorly soluble drugs
TW201129385A (en) Film-coating agent for solid formulation and solid formulation using the same
WO2009094457A3 (en) Substituted benzhydrylethers
WO2006044771A3 (en) Methods and compositions for reducing toxicity of a pharmaceutical compound
WO2008042841A3 (en) Docetaxel compositions
WO2010080754A3 (en) Nanoparticle pharmaceutical formulations
WO2012053768A3 (en) Aryloxyphenoxyacetyl-based compound having hif-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient
WO2011056785A3 (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2011073222A3 (en) Hyperbranched polyester having a hydrophobic core for solubilizing active ingredients of low solubility
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
WO2012019428A8 (en) Benzohydrol derivatives, a preparation process and pharmaceutical use thereof
WO2009084036A3 (en) Composition for treatment of viral infections
WO2010013835A3 (en) Solid pharmaceutical composition
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
WO2008084823A1 (en) Brown coating composition and method for preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10807512

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10807512

Country of ref document: EP

Kind code of ref document: A2